

2nd December 2025

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

- Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand). I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column:**

July through September 2025	Age											
Brand name (scientific)	0-12 years						13+					
	Mild		Moderate		Severe		Mild		Moderate		Severe	
	PPx	OD	PPx	OD	PPx	OD	PPx	OD	PPx	OD	PPx	OD
Hemlibra (emicizumab)	0	0	0	0	0	0	0	0	0	0	0	0
Altuvect (giiroctocogene fitelparvovec)	0	0	0	0	0	0	0	0	0	0	0	0
Esperoct (turoctocog alfa pegol)	0	0	0	0	0	0	0	0	0	0	0	0
Elocta (efmoroctocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
Advate (octocog alfa)	0	0	0	0	0	0	0	0	0	1	0	0
Kovaltry (octocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
Iblias (octocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
Refacto AF (moroctocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
Xyntha (moroctocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
NovoEight (turoctocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
Nuwiq (simoctocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0
Vihuma (simoctocog alfa)	0	0	0	0	0	0	0	0	0	0	0	0

Inhibitor patients

- 2) For Hemlibra-treated Hemophilia A Inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

Age group (Hemophilia A inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years	0	0	0
13+ years	0	0	0
Total	0	0	0

Non-inhibitor patients

- 3) For Hemlibra-treated Hemophilia A non-inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

Age group (Hemophilia A non-inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years	0	0	0
13+ years	0	0	0
Total	0	0	0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net